Advertisement

Strahlentherapie und Onkologie

, Volume 194, Issue 1, pp 9–16 | Cite as

Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy

A national survey on patterns of practice
  • Alan Dal Pra
  • Cedric Panje
  • Thomas Zilli
  • Winfried Arnold
  • Kathrin Brouwer
  • Helena Garcia
  • Markus Glatzer
  • Silvia Gomez
  • Fernanda Herrera
  • Khanfir Kaouthar
  • Alexandros Papachristofilou
  • Gianfranco Pesce
  • Christiane Reuter
  • Hansjörg Vees
  • Daniel Rudolf Zwahlen
  • Daniel Engeler
  • Paul Martin Putora
Original Article

Abstract

Introduction

Although salvage radiotherapy (SRT) for PSA recurrence after radical prostatectomy provides better oncological outcomes when delivered early, in the absence of detectable disease many patients are treated for macroscopic locally recurrent tumors. Due to limited data from prospective studies, we hypothesized an important variability in the SRT management of these patients. Our aim was to investigate current practice patterns of SRT for local macroscopic recurrence after radical prostatectomy.

Material and methods

A total of 14 Swiss radiation oncology centers were asked to complete a survey on treatment specifications for macroscopic locally recurrent disease including information on pretherapeutic diagnostic procedures, dose prescription, radiation delivery techniques and androgen deprivation therapy (ADT). Treatment recommendations on ADT were analyzed using the objective consensus methodology.

Results

The majority of centers recommended pretreatment magnetic resonance imaging (MRI) of the pelvis and choline positron emission tomography (PET). The median prescribed dose to the prostate bed was 66 Gy (range 65–72 Gy) with a boost to the macroscopic lesion used by 79% of the centers with a median total dose of 72 Gy (range 70–80 Gy). Intensity-modulated rotational techniques were used by all centers and daily cone beam computed tomography (CT) was recommended by 43%. The use of concomitant ADT for any macroscopic recurrence was recommended by 43% of the centers while the remaining centers recommended it only for high-risk disease, which was not consistently defined.

Conclusion

We observed a high variability of treatment paradigms when SRT is indicated for macroscopic local recurrences after prostatectomy. These data reflect the need for more standardized approaches and ultimately further research in this field.

Keywords

Postoperative radiotherapy Salvage radiotherapy Prostate cancer Radiotherapy Macroscopic recurrence 

Salvage-Radiotherapie bei makroskopischen Lokalrezidiven nach radikaler Prostatektomie

Nationale Umfrage zu Behandlungsmustern

Zusammenfassung

Einleitung

Obwohl die Evidenz für eine frühzeitige Salvage-Radiotherapie (SRT) bei einem PSA-Rezidiv nach radikaler Prostatektomie spricht, werden viele Patienten erst bei einem makroskopischen Lokalrezidiv behandelt. Hier scheint es jedoch aufgrund der fehlenden Daten aus prospektiven Studien eine Variabilität der Behandlungskonzepte zu geben. Das Ziel der Studie war es, die aktuelle Behandlungspraxis in der SRT des makroskopischen Rezidivs eines Prostatakarzinoms zu untersuchen.

Material und Methoden

Insgesamt 14 Schweizer Strahlentherapiezentren wurden für eine Umfrage zu den Behandlungsparametern beim makroskopischen Lokalrezidiv eines Prostatakarzinoms kontaktiert und nach diagnostischen Maßnahmen, Dosisverschreibung, Strahlentherapietechniken und antihormoneller Therapie (ADT) befragt. Die variierenden Indikationen zur ADT wurden mittels der Objective-konsensus-Methodologie ausgewertet.

Ergebnisse

Die Mehrheit der Zentren empfahl vor der Therapie eine Magnetresonanztomographie (MRT) des Beckens und eine Cholin-Positronenemissionstomographie (PET). Die mediane verschriebene Dosis für die Prostataloge war 66 Gy (65–72 Gy) mit einem Boost auf das makroskopische Lokalrezidiv in 79 % der Zentren bis zu einer medianen Dosis von 72 Gy (70–80 Gy). Alle Zentren verwendeten intensitätsmodulierte Rotationstechniken, ein tägliches Cone-beam-CT wurde in 43 % der Zentren empfohlen. Eine begleitende ADT wurde von 43 % für jedes makroskopische Lokalrezidiv empfohlen, während die übrigen Zentren dies nur bei Hochrisikogruppen (mit unterschiedlichen Definitionen) durchführten.

Schlussfolgerung

Es wurde eine hohe Variabilität der Behandlungskonzepte für die SRT des makroskopischen Lokalrezidivs nach Prostatektomie beobachtet. Dies zeigt den Bedarf an standardisierten Behandlungskonzepten und weiteren Studien in diesem Bereich auf.

Schlüsselwörter

Postoperative Strahlentherapie Salvage-Radiotherapie Prostatakarzinom Strahlentherapie Makroskopisches Rezidiv 

Notes

Acknowledgements

ADP and CP contributed equally to the manuscript.

Compliance with ethical guidelines

Conflict of interest

A. Dal Pra, C. Panje, T. Zilli, W. Arnold, K. Brouwer, H. Garcia, M. Glatzer, S. Gomez, F. Herrera, K. Kaouthar, A. Papachristofilou, G. Pesce, C. Reuter, H. Vees, D. Zwahlen, D. Engeler and P.M. Putora declare that they have no competing interests.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Ward JF, Moul JW (2005) Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2(4):174–182. doi: 10.1038/ncpuro0145 CrossRefPubMedGoogle Scholar
  2. 2.
    Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED (2007) Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25(16):2225–2229. doi: 10.1200/JCO.2006.09.6495 CrossRefPubMedGoogle Scholar
  3. 3.
    Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M, Rube C, Weissbach L, Althaus P, Rebmann U, Kalble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J Clin Oncol 27(18):2924–2930. doi: 10.1200/JCO.2008.18.9563 CrossRefPubMedGoogle Scholar
  4. 4.
    Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962. doi: 10.1016/j.juro.2008.11.032 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018–2027. doi: 10.1016/s0140-6736(12)61253-7 CrossRefPubMedGoogle Scholar
  6. 6.
    Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ (2016) Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. doi: 10.1200/jco.2016.67.9647 PubMedGoogle Scholar
  7. 7.
    Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A (2016) Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 69(4):728–733. doi: 10.1016/j.eururo.2015.10.009 CrossRefPubMedGoogle Scholar
  8. 8.
    Amzalag G, Rager O, Tabouret-Viaud C, Wissmeyer M, Sfakianaki E, de Perrot T, Ratib O, Miralbell R, Giovacchini G, Garibotto V, Zilli T (2016) Target definition in salvage radiotherapy for recurrent prostate cancer: the role of advanced molecular imaging. Front Oncol 6:73. doi: 10.3389/fonc.2016.00073 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N’Guyen TD, Suchaud JP, Crehange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17(6):747–756. doi: 10.1016/s1470-2045(16)00111-x CrossRefPubMedGoogle Scholar
  10. 10.
    Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Holscher T, Gut P, Guckenberger M, Hildebrandt G, Muller AC, Plasswilm L, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbuhler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Kaouthar K, Wust P, Thalmann GN, Aebersold DM (2015) Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 33(35):4158–4166. doi: 10.1200/jco.2015.63.3529 CrossRefPubMedGoogle Scholar
  11. 11.
    Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM (2017) Radiation with or without Antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376(5):417–428. doi: 10.1056/NEJMoa1607529 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Radiation Therapy Oncology Group (2015) RTOG 0534 Protocol Information. https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0534. Accessed 14 Feb 2017Google Scholar
  13. 13.
    Putora P, Panje CM, Papachristofilou A, Pra A, Hundsberger T, Plasswilm L (2014) Objective consensus from decision trees. Radiat Oncol 9(1):270. doi: 10.1186/s13014-014-0270-y CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Panje CM, Dal Pra A, Zilli T, Zwahlen DR, Papachristofilou A, Herrera FG, Matzinger O, Plasswilm L, Putora PM (2015) Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice. Strahlenther Onkol 191(10):778–786. doi: 10.1007/s00066-015-0849-8 CrossRefPubMedGoogle Scholar
  15. 15.
    Michalski JM, Lawton C, El Naqa I, Ritter M, O’Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Menard C (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76(2):361–368. doi: 10.1016/j.ijrobp.2009.02.006 CrossRefPubMedGoogle Scholar
  16. 16.
    Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh AC, Scrase C, Van Poppel H, Bolla M (2007) Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84(2):121–127. doi: 10.1016/j.radonc.2007.07.017 CrossRefPubMedGoogle Scholar
  17. 17.
    D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRefPubMedGoogle Scholar
  18. 18.
    Center MSKC Memorial Sloan Kettering Cancer Center (2017) Prostate cancer nomograms. https://www.mskcc.org/nomograms/prostate. Accessed 14 Feb 2017Google Scholar
  19. 19.
    Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150(1):110–114CrossRefPubMedGoogle Scholar
  20. 20.
    Roach M 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28(1):33–37CrossRefPubMedGoogle Scholar
  21. 21.
    Hegemann NS, Morcinek S, Buchner A, Karl A, Stief C, Knuchel R, Corradini S, Li M, Belka C, Ganswindt U (2016) Risk of biochemical recurrence and timing of radiotherapy in pT3a N0 prostate cancer with positive surgical margin: a single center experience. Strahlenther Onkol 192(7):440–448. doi: 10.1007/s00066-016-0990-z CrossRefPubMedGoogle Scholar
  22. 22.
    Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Chiorda BN, Gandaglia G, Dell’Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A (2016) Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. Eur Urol. doi: 10.1016/j.eururo.2016.07.028 Google Scholar
  23. 23.
    King CR (2012) The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 84(1):104–111. doi: 10.1016/j.ijrobp.2011.10.069 CrossRefPubMedGoogle Scholar
  24. 24.
    Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr., Faraday MM (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 190(2):441–449. doi: 10.1016/j.juro.2013.05.032 CrossRefPubMedGoogle Scholar
  25. 25.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2016) EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. doi: 10.1016/j.eururo.2016.08.002 Google Scholar
  26. 26.
    Sobol I, Zaid HB, Haloi R, Mynderse LA, Froemming AT, Lowe VJ, Davis BJ, Kwon ED, Karnes RJ (2017) Contemporary mapping of post-prostatectomy prostate cancer relapse with 11C-choline positron emission tomography and multiparametric magnetic resonance imaging. J Urol 197(1):129–134. doi: 10.1016/j.juro.2016.07.073 CrossRefPubMedGoogle Scholar
  27. 27.
    Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive 68 ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and Meta-analysis. Eur Urol 70(6):926–937. doi: 10.1016/j.eururo.2016.06.021 CrossRefPubMedGoogle Scholar
  28. 28.
    Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, Azria D, Beckendorf V, Suchaud JP, Bernier V, Perol D, Carrie C (2016) Is there a role for pelvic irradiation in localized prostate Adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 96(4):759–769. doi: 10.1016/j.ijrobp.2016.06.2455 CrossRefPubMedGoogle Scholar
  29. 29.
    Roach M 3rd, DeSilvio M, Lawton C et al (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911Google Scholar
  30. 30.
    Song C, Kang HC, Kim JS, Eom KY, Kim IA, Chung JB, Hong SK, Byun SS, Lee SE (2015) Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: a propensity score-matched analysis. Strahlenther Onkol 191(10):801–809. doi: 10.1007/s00066-015-0872-9 CrossRefPubMedGoogle Scholar
  31. 31.
    Fossati N, Willemse PM, van den Bergh RC, Van den Broeck T, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S (2017) The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol. doi: 10.1016/j.eururo.2016.12.003 Google Scholar
  32. 32.
    Dal Pra A, Cury FL, Souhami L (2010) Combining radiation therapy and androgen deprivation for localized prostate cancer – a critical review. Curr Oncol 17(5):28–38Google Scholar
  33. 33.
    Carrie C, Hasbini A, De Laroche G, Habibian M, Richaud P, Guérif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N’Guyen TD, Suchaud JP, Crehange G, Barbier N, Ruffion A, Dussart S (2015) Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial – NCT00423475. J Clin Oncol 33(15_suppl):5006 (ASCO Annual Meeting (May 29 – June 2, 2015))Google Scholar
  34. 34.
    Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB (2015) What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 115(3):295–300. doi: 10.1016/j.radonc.2015.05.011 CrossRefPubMedGoogle Scholar
  35. 35.
    Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ (2011) Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol 60(6):1142–1148. doi: 10.1016/j.eururo.2011.08.006 CrossRefPubMedGoogle Scholar
  36. 36.
    Ost P, Lumen N, Goessaert AS, Fonteyne V, De Troyer B, Jacobs F, De Meerleer G (2011) High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5‑year results. Eur Urol 60(4):842–849. doi: 10.1016/j.eururo.2011.04.021 CrossRefPubMedGoogle Scholar
  37. 37.
    Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R, Di Muzio N (2009) IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 93(2):207–212. doi: 10.1016/j.radonc.2009.08.042 CrossRefPubMedGoogle Scholar
  38. 38.
    Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52(1):6–13CrossRefPubMedGoogle Scholar
  39. 39.
    Li XA, Wang JZ, Jursinic PA, Lawton CA, Wang D (2005) Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 61(4):1251–1257. doi: 10.1016/j.ijrobp.2004.11.034 CrossRefPubMedGoogle Scholar
  40. 40.
    Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF (2016) A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. doi: 10.1016/s1470-2045(16)30648-9 Google Scholar
  41. 41.
    Stoyanova R, Pollack A, Takhar M, Lynne C, Parra N, Lam LL, Alshalalfa M, Buerki C, Castillo R, Jorda M, Ashab HA, Kryvenko ON, Punnen S, Parekh DJ, Abramowitz MC, Gillies RJ, Davicioni E, Erho N, Ishkanian A (2016) Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget 7(33):53362–53376. doi: 10.18632/oncotarget.10523 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2017

Authors and Affiliations

  • Alan Dal Pra
    • 1
  • Cedric Panje
    • 2
  • Thomas Zilli
    • 3
  • Winfried Arnold
    • 4
  • Kathrin Brouwer
    • 5
  • Helena Garcia
    • 6
  • Markus Glatzer
    • 2
  • Silvia Gomez
    • 7
  • Fernanda Herrera
    • 8
  • Khanfir Kaouthar
    • 9
  • Alexandros Papachristofilou
    • 10
  • Gianfranco Pesce
    • 11
  • Christiane Reuter
    • 12
  • Hansjörg Vees
    • 13
  • Daniel Rudolf Zwahlen
    • 14
  • Daniel Engeler
    • 15
  • Paul Martin Putora
    • 2
  1. 1.Department of Radiation OncologyBern University Hospital, Inselspital BernBernSwitzerland
  2. 2.Department of Radiation OncologyKantonsspital St. GallenSt. GallenSwitzerland
  3. 3.Department of Radiation OncologyHospitaux Universitaires de GénèveGénèveSwitzerland
  4. 4.Department of Radiation OncologyLuzerner KantonsspitalLuzernerSwitzerland
  5. 5.Department of Radiation OncologyStadtspital TriemliZürichSwitzerland
  6. 6.Department of Radiation OncologyUniversitätsspital ZürichZürichSwitzerland
  7. 7.Department of Radiation OncologyKantonsspital AarauAarauSwitzerland
  8. 8.Department of Radiation OncologyCentre Hospitalier Universitaire VaudoisLausanneSwitzerland
  9. 9.Department of Radiation OncologyHôpital du ValaisSionSwitzerland
  10. 10.Department of Radiation OncologyUniversitätsspital BaselBaselSwitzerland
  11. 11.Department of Radiation OncologyEOC BellinzonaBellinzonaSwitzerland
  12. 12.Department of Radiation OncologyKantonsspital MünsterlingenMünsterlingenSwitzerland
  13. 13.Department of Radiation OncologyKlinik HirslandenZürichSwitzerland
  14. 14.Department of Radiation OncologyKantonsspital GraubündenChurSwitzerland
  15. 15.Department of UrologyKantonsspital St. GallenSt. GallenSwitzerland

Personalised recommendations